Engineered viral vectors with enhanced packaging capacity and methods of using the same
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology
InventorsFeng ZHANG, Victoria MADIGAN
Life of this patent
Estimating the term…
Abstract
Provided are engineered viral vectors, compositions comprising viral vectors, and methods of producing and using engineered viral vectors. The engineered viral vectors provided herein include capsid proteins derived from densovirus (DNV). Such DNV capsid proteins can assemble in mammalian cells and encapsulate adeno-associated virus (AAV) and/or DNV genomic DNA. The engineered viral vectors may be used as delivery vectors in target gene therapies.
Claims25
An engineered viral vector for delivery of a transgene into a mammalian cell, comprising
- (i) a densovirus (DNV) capsid, and
- (ii) a nucleic acid molecule comprising a transgene.
(canceled)
(canceled)
A method of delivering a transgene into a mammalian cell, comprising contacting the mammalian cell with an engineered viral vector, the engineered viral vector comprising
- (i) a DNV capsid;
- and
- (ii) a nucleic acid molecule comprising a transgene.
-20. (canceled)
A vector system comprising one or more vectors for producing an engineered viral vector, wherein the one or more vectors comprise:
- a DNV cap gene encoding a DNV capsid protein;
- a rep gene encoding an engineered replicase capable of interacting with the DNV capsid protein;
- a transgene linked to an ITR sequence;
- and optionally, a helper gene.
(canceled)
(canceled)
-47. (canceled)
Dependencies are inferred from the claim text.